|
gptkbp:instance_of
|
gptkb:immunotherapy
|
|
gptkbp:approves
|
gptkb:1998
gptkb:FDA
|
|
gptkbp:associated_with
|
improved quality of life
increased life expectancy
reduced viral load
improved immune function
lower risk of opportunistic infections
|
|
gptkbp:available_on
|
gptkb:Software_Solutions
gptkb:tablet
|
|
gptkbp:brand
|
gptkb:Ziagen
|
|
gptkbp:can_be_combined_with
|
gptkb:lamivudine
gptkb:tenofovir
gptkb:zidovudine
gptkb:emtricitabine
|
|
gptkbp:chemical_formula
|
C14 H18 N6 O
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
|
|
gptkbp:contraindication
|
gptkb:HLA-B*5701_allele
|
|
gptkbp:discovered_by
|
gptkb:Glaxo_Smith_Kline
|
|
gptkbp:dosage_form
|
300 mg twice daily
600 mg once daily
|
|
gptkbp:drug_interactions
|
gptkb:beer
|
|
gptkbp:formulation
|
fixed-dose combination
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
abacavir
|
|
gptkbp:invention
|
gptkb:2018
|
|
gptkbp:lifespan
|
1.5 hours
|
|
gptkbp:marketed_as
|
gptkb:Glaxo_Smith_Kline
multiple countries
|
|
gptkbp:mechanism_of_action
|
NRTI (nucleoside reverse transcriptase inhibitor)
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pharmacokinetics
|
hepatic metabolism
bioavailability 83%
protein binding 50%
renal excretion 62%
|
|
gptkbp:provides_guidance_on
|
gptkb:ART_(antiretroviral_therapy)
HAART (highly active antiretroviral therapy)
|
|
gptkbp:research_focus
|
drug efficacy
treatment adherence
long-term effects
HIV resistance
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety_measures
|
liver function tests
viral load
CD4 count
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
diarrhea
rash
hypersensitivity reaction
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:used_for
|
treatment of HIV
|
|
gptkbp:bfsParent
|
gptkb:Dovato
gptkb:Triumeq
gptkb:Retrovir
gptkb:lamivudine
gptkb:nucleoside_reverse_transcriptase_inhibitor
gptkb:zidovudine
|
|
gptkbp:bfsLayer
|
6
|